Select Language
CD3 epsilon
CD3 epsilon Overview
| English Name | T-cell surface glycoprotein CD3 epsilon chain | Approved Drugs | 4 |
| Drugs in Clinical Trials | 7 | Target Synonym | T-cell surface antigen T3/Leu-4 epsilon chain，CD3-Epsilon |
| Highest Development Stage | Approved | ||
| English Name | T-cell surface glycoprotein CD3 epsilon chain |
| Target Synonym | T-cell surface antigen T3/Leu-4 epsilon chain，CD3-Epsilon |
| Approved Drugs | 4 |
| Drugs in Clinical Trials | 7 |
| Highest Development Stage | Approved |
CD3 epsilon Product List
- Product Category
Protein (18)Beads (1)
- Product Status
Launched (19)
- Species
Human (10)Cynomolgus (5)Mouse (2)Canine (1)Rhesus macaque (1)
- Tag
His Tag (8)His Tag & Fc Tag (2)Fc Tag (4)His Tag & Avi Tag (1)Mouse IgG Fc Tag (1)- (1)Fc Tag & Avi Tag (2)
- Conjugate
Unconjugated (10)Biotin-labeled (5)- (1)HRP Labeled (1)AF488 Labeled (2)
Total: 19
- 1
- 2
CD3 epsilon Background
CD3e molecule, epsilon is also known as CD3E, is a T-cell surface single-pass type I membrane glycoprotein. CD3E contains 1 Ig-like (immunoglobulin-like) domain and 1 ITAM domain. CD3E, together with CD3-gamma, CD3-delta and CD3-zeta, and the T-cell receptor alpha/beta and gamma/delta heterodimers, forms the T cell receptor-CD3 complex. This complex plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. The genes encoding the epsilon, gamma and delta polypeptides are located in the same cluster on chromosome 11. The epsilon polypeptide plays an essential role in T-cell development. CD3E plays an essential role in T-cell development, and defects in CD3E gene cause severe immunodeficiency. CD3E gene has also been linked to a susceptibility to type I diabetes in women. CD3E has been shown to interact with TOP2B, CD3EAP and NCK2.
CD3 epsilon Synonyms
FLJ18683,T3E,TCRE,CD3E,CD3-epsilon
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Foralumab | NI-0401/α-CD3; TZLS-401; NI-0401 | Phase 2 Clinical | Medarex Inc, Novimmune Sa | Alzheimer Disease; Amyotrophic Lateral Sclerosis; Cognitive Dysfunction; Coronavirus Disease 2019 (COVID-19); Crohn Disease; Dementia; Diabetes Mellitus, Type 2; Lower Respiratory Tract Infections; Metabolic Dysfunction-Associated Steatotic Liver Disease; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple System Atrophy; Rejection of renal transplantation | Details |
| Obrindatamab | MGD-009; B7-H3 x CD3 | Phase 2 Clinical | Macrogenics Inc | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colonic Neoplasms; Melanoma; Mesothelioma; Neuroblastoma; Neurofibrosarcoma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rhabdomyosarcoma; Sarcoma; Sarcoma, Synovial; Squamous Cell Carcinoma of Head and Neck; Thyroid Neoplasms; Urinary Bladder Neoplasms; Wilms Tumor | Details |
| SOA-101 | SOA-101; SOA101 | Phase 2 Clinical | Shine-On BioMedical Co Ltd | Brain Neoplasms; Breast Neoplasms; Lung Neoplasms; Mouth Neoplasms; Ovarian Neoplasms; Solid tumours | Details |
| Emerfetamab | AMG-673; AMG673 | Phase 1 Clinical | Amgen Inc | Leukemia, Myeloid, Acute | Details |
| Gresonitamab | AMG-910 | Phase 1 Clinical | Amgen Inc | Adenocarcinoma; Esophageal Neoplasms; Stomach Neoplasms | Details |
| Eluvixtamab | AMG-330; MT-114 | Phase 1 Clinical | Amgen Inc | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| Linclatamig | BLYG-8824; BLYG-8824A; RG 6286 | Phase 1 Clinical | Genentech Inc | Colorectal Neoplasms | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Tarlatamab | AMG-757 | Approved | Amgen Inc | Imdelltra | United States | Small Cell Lung Carcinoma | Amgen Inc | 2024-05-16 | Astrocytoma; Brain metastases; Carcinoma, Merkel Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Ganglioglioma; Glioblastoma; Medullary thyroid cancer (MTC); Melanoma; Neoplasms; Neuroendocrine Tumors; Oligodendroglioma; Paranasal Sinus Diseases; Prostatic Neoplasms; Small Cell Lung Carcinoma; Testicular Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | Details |
| Elranatamab | PF‑3135; RN-613; PF-06863135 | Approved | Pfizer Inc | Elrexfio, ELREXFIO™, ELREXFIO | United States | Multiple Myeloma | Pfizer Inc | 2023-08-14 | Anemia, Hemolytic, Autoimmune; Bone Marrow Neoplasms; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Smoldering Multiple Myeloma; Spinal Cord Diseases | Details |
| Glofitamab | RG-6026; RO-7082859; RG6026-2; RO6026 | Approved | F. Hoffmann-La Roche Ltd | COLUMVI, 高罗华 | Canada | Lymphoma, Large B-Cell, Diffuse | F. Hoffmann-La Roche Ltd | 2023-03-25 | Central Nervous System Lymphoma; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin | Details |
| Talquetamab | JNJ-7564; JNJ-64407564 | Approved | Genmab A/S, Johnson & Johnson Innovative Medicine | TALVEY, 拓立珂 | United States | Multiple Myeloma | Janssen Biotech Inc | 2023-08-09 | Hematologic Neoplasms; Multiple Myeloma | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to: